by pulsepartner | Jul 2, 2026 | Blog Post
Policymakers in California, New York and across the country are considering state-level antitrust proposals that could chill innovation, competition and growth in key industries, including life sciences. The risk of misaligned state antitrust standards is especially...
by Keishi Foecke | Jun 10, 2026 | Blog Post
In recent comments to the Department of Justice (DOJ) and Federal Trade Commission (FTC), PULSE highlighted critical reforms to ensure that U.S. competition policies support – and do not impede – the pro-competitive mergers and acquisitions (M&A) and other...
by pulsepartner | May 26, 2026 | PULSE Partner
PULSE recently sat down with Debbie Hart, President and CEO at BioNJ, the life sciences trade association for New Jersey. Established more than 30 years ago, BioNJ represents over 400 research-based life sciences organizations across the health care ecosystem – from...
by pulsepartner | Apr 29, 2026 | Blog Post
Findings from Citeline’s latest report, Pharma R&D Annual Review 2026, highlight the continued U.S. leadership in the life sciences ecosystem. As the report acknowledges, life sciences mergers and acquisitions (M&A) play a critical role in preserving American...
by pulsepartner | Apr 8, 2026 | Blog Post
A recent report from the Information Technology and Innovation Foundation (ITIF), “Antitrust Undone: How Competition Enforcers Are Undermining Competition,” highlights the risks of unnecessarily aggressive antitrust enforcement in innovative industries. The report...
by pulsepartner | Mar 5, 2026 | Innovations Advanced by M&A
This blog is another installment in a series, Innovations Advanced by M&A, that underscores the unique role of mergers and acquisitions in promoting a competitive and innovative life sciences ecosystem for patients. You can find previous blogs in this...
